Sansure Biotech Inc.

SHSE:688289 Stock Report

Market Cap: CN¥13.9b

Sansure Biotech Past Earnings Performance

Past criteria checks 0/6

Sansure Biotech's earnings have been declining at an average annual rate of -16.3%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been declining at an average rate of 3.1% per year. Sansure Biotech's return on equity is 2.9%, and it has net margins of 18.4%.

Key information

-16.3%

Earnings growth rate

-16.7%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate-3.1%
Return on equity2.9%
Net Margin18.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Nov 03
Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

May 03
Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

Recent updates

Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Nov 03
Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Oct 09
Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital

Oct 03
Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital

Is Sansure Biotech (SHSE:688289) A Risky Investment?

Sep 12
Is Sansure Biotech (SHSE:688289) A Risky Investment?

Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected

Aug 21
Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected

Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital

Jun 03
Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital

Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

May 03
Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Apr 26
Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Feb 28
Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Revenue & Expenses Breakdown

How Sansure Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688289 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,407259733247
30 Jun 241,296429676222
31 Mar 241,203385642204
31 Dec 231,007364552195
30 Sep 233,015638868289
30 Jun 234,188904930321
31 Mar 235,2061,345949334
31 Dec 226,4501,937985331
30 Sep 225,3162,084599276
30 Jun 225,1762,247568235
31 Mar 224,7912,272499208
31 Dec 214,5152,243507187
30 Sep 214,4252,361464111
30 Jun 214,6912,506566106
31 Mar 215,5263,04667295
31 Dec 204,7632,61762783
30 Sep 203,7272,03457576
30 Jun 202,2991,26335550
31 Mar 2068323321140
31 Dec 193653916139
31 Dec 18303713435
31 Dec 17225-1110528

Quality Earnings: 688289 has a large one-off gain of CN¥114.7M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 688289's current net profit margins (18.4%) are lower than last year (21.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688289's earnings have declined by 16.3% per year over the past 5 years.

Accelerating Growth: 688289's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688289 had negative earnings growth (-59.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (-8.8%).


Return on Equity

High ROE: 688289's Return on Equity (2.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies